Medical News: Huarun below the issue price of shares fell nearly 3% Sina App: Live on-line blogger to guide Sina Hong Kong APP: real time market exclusive reference stocks also worth the investment? What’s the problem? Where is the future of the way out? Sina launched the "Hong Kong Hong Kong stocks as well as unattractive" discussion, with a rational and constructive attitude, welcome attention to Hong Kong stocks, concern of the capital market, Hong Kong stocks together for suggestions, seek the Hong Kong stock market tomorrow. Please to hkstock_biz@sina. Sina Hong Kong News October 28th news of Huarun group, Huarun medical (03320.HK) today listed on this morning, Huarun medical flat open after the way down below the issue price, as of press time, Huarun pharmaceutical fell 2.75% to HK $8.85, turnover of 649 million 700 thousand, Volume 71 million 810 thousand shares. The stock price of the lowest dark to see 8.5 yuan, compared with the IPO price of 9.1 yuan, down 6.6%, to close at 8.89 yuan, or 0.21 yuan low IPO price of 2.3%, turnover of 1 million 200 thousand shares, involving capital 10 million 500 thousand yuan. Huarun Pharmaceutical (03320) announcement, the company issued 1 billion 543 million shares, the sale price of HK $9.10 per share (units), the net proceeds of approximately 13 billion 671 million yuan, 500 shares per hand, the success rate is 100%. Huarun Hongkong public offering has been slightly oversubscribed, was 0.9 times oversubscribed. International offering has been slightly oversubscribed, the final number of shares issued for the international offering of 1 billion 465 million shares. According to the final issue price and the cornerstone of the investment agreement, the cornerstone investors has an aggregate of 781 million shares, including Heng Jian, Chinese investment life insurance, Fuji Photo Film Co, Nordic bank, (Asia) International London Trading Limited, Chinese Chengtong and High Action Limited, Ampang investment. Equivalent to 12.65% of the total issued share capital of the company after the completion of the global offering; and the number of shares sold worldwide, the number of 50.61%. According to the prospectus, Huarun medicine the IPO fund-raising plans for the acquisition of 45% Chinese strategy to expand the pharmaceutical and pharmaceutical distribution business, the remaining funds will be used to build more logistics center and warehouse, investment in research and technology upgrade system and repay debt. It is reported that Huarun pharmaceutical business, including pharmaceutical, pharmaceutical distribution, pharmaceutical retail. You can see from the prospectus, Huarun Pharma’s current total production and marketing of 494 kinds of drugs, including 6 kinds of pharmaceutical products in the annual income of more than HK $1 billion, including gelatin block, basic infusion, Ganmaoling, Fej, and No. 0 Chinese medicinal granules. Data show that the total income of Huarun medicine in the past three years and the profits are increasing year by year. 2015, Huarun’s total revenue of HK $146 billion 568 million (about 125 billion 550 million yuan), profit of HK $6 billion 80 million in the year (about $5 billion 200 million), gross margin was 15.8%. Theory of Thailand相关的主题文章: